ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: As revealed by targeting of the BCR::ABL1 fusion with tyrosine kinase inhibitors in CML and del(5q) mutated cells with lenalidomide, the leukemic stem cells are particularly challenging to eliminate fully.